China’s Respiratory Sector Luring Multinationals
This article was originally published in PharmAsia News
China has about 30 million people suffering from asthma, and just over 8% of the population aged above 40 has chronic obstructive pulmonary disease (COPD), compared with 3% in neighboring India, Chinese authorities said at a forum on innovative drug delivery technology held earlier this year in Suzhou.
You may also be interested in...
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.